Sanofi Pasteur and Immune Design Collaborate on a Vaccine to Treat HSV
News Oct 18, 2014
Sanofi Pasteur and Immune Design Corp. have announced that they have entered into a broad collaboration for the development of a herpes simplex virus (HSV) immune therapy.
Sanofi Pasteur and Immune Design will each contribute product candidates to the collaboration: Sanofi Pasteur will contribute HSV-529, a clinical-stage replication-defective HSV vaccine product candidate, and Immune Design will contribute G103, its preclinical trivalent vaccine product candidate.
The collaboration will explore the potential of various combinations of agents, including Immune Design’s GLAAS™ platform, with the goal to select the best potential immune therapy for patients.
“We intend to develop the best in class HSV therapeutic vaccine by pooling assets of Sanofi Pasteur and of Immune Design,” explained John Shiver, PhD, Senior VP for R&D, Sanofi Pasteur. “Given the challenges of vaccine development,” Shiver continued, “collaborations are important to help ensure that the medical need will eventually be met.”
The two companies will develop the products jointly through Phase II clinical trials, at which point Sanofi Pasteur intends to continue development of the most promising candidate and be responsible for commercialization.
Sanofi Pasteur will bear the costs of all preclinical and clinical development, with Immune Design providing a specific formulation of GLA from the GLAAS platform at its cost through Phase II studies.
Immune Design will be eligible to receive future milestone and royalty payments on any product developed from the collaboration; other financial terms of the agreement have not been disclosed.
Macrophage's Role in Maintaining Tattoos Could Hold Key to RemovalNews
Researchers have discovered that, though a tattoo may be forever, the skin cells that carry the tattoo pigment are not. Instead, the cells can pass on the pigment to new cells when they die. The study suggests ways to improve the ability of laser surgery to remove unwanted tattoos.READ MORE
New Causes of Cellular Decline in Prematurely Aging Kids DiscoveredNews
In a recent paper published in Cell Reports, Saint Louis University researchers have uncovered new answers about why cells rapidly age in children with a rare and fatal disease. The data points to cellular replication stress and a mistaken innate immune response as culprits, and the team found success in the laboratory in blocking these processes with vitamin D.READ MORE
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE